
Please try another search
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Name | Age | Since | Title |
---|---|---|---|
Richard A. van den Broek | 59 | 2020 | Independent Director |
Mahkam Zanganeh | 55 | 2017 | Independent Director |
Manmeet Singh Soni | 47 | 2017 | Lead Independent Director |
Darrin R. Uecker | 59 | 2015 | CTO & Director |
Robert W. Duggan | 80 | 2017 | Independent Co-Chairman |
Paul Arthur LaViolette | 67 | 2024 | President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review